Efficacy of isothiocyanate-based compounds on different forms of persistent pain
Received 8 January 2018
Accepted for publication 5 July 2018
Published 19 November 2018 Volume 2018:11 Pages 2905—2913
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Erica Wegrzyn
Elena Lucarini,1 Laura Micheli,1 Alma Martelli,2 Lara Testai,2 Vincenzo Calderone,2 Carla Ghelardini,1 Lorenzo Di Cesare Mannelli1
1Pharmacology and Toxicology Section, Department of Neuroscience, Psychology, Drug Research, and Child Health (Neurofarba), University of Florence, Florence, Italy; 2Department of Pharmacy, University of Pisa, Pisa, Italy
Purpose: Current pharmacotherapy for persistent pain related to neuropathy or articular diseases is unsatisfactory, due to the large number of unresponsive patients and side effects. Isothiocyanates (ITCs) are a class of natural or synthetic compounds characterized by the general formula R–NCS. ITCs show antihyperalgesic effects in models of central and peripheral nervous tissue injury and anti-inflammatory properties. The pharmacodynamics are strictly related to the release of the gasotransmitter hydrogen sulfide (H2S) from their moiety. In particular, phenyl ITC (PITC) and 3-carboxyphenyl ITC (3C-PITC) exhibit interesting slow H2S-release properties suitable for treating painful pathology. The aim of the present work was to evaluate the efficacy of PITC and 3C-PITC against mechanical hyperalgesia and spontaneous pain induced by nerve injury and osteoarthritis.
Methods: Nerve injury and osteoarthritis were induced in rats by ligation of the sciatic nerve (chronic constriction injury) and intra-articular injection of monoiodoacetate, respectively. Behavioral tests were performed 14 days after damage induction.
Results: Single subcutaneous administrations of PITC, 3C-PITC (4.43 and 13.31 µmol kg-1, respectively) were able to completely reverse hypersensitivity to noxious stimuli in both models of neuropathic and osteoarticular pain. The effect of ITCs was compared with that of NaHS, the prototypical H2S donor, showing similar efficacy and higher potency. ITCs and NaHS also reduced spontaneous pain.
Conclusion: ITCs offer a promising novel approach to counteract persistent, drug-resistant painful pathology.
Keywords: neuropathic pain, nerve injury, osteoarthritis, isothiocyanate, H2S
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]